High-dose intensity regimens with epirubicin in ovarian cancer
Vermorken, J.B.
Pathologie-Biologie 39(9): 833
1992
ISSN/ISBN: 0369-8114 PMID: 1538894 Document Number: 403239
Document emailed within 1 workday
Related Documents
Rosell, R.; Gómez-Codina, J.; Anton, A.; Sánchez, J.J.; Vadell, C. 1994: Escalating high-dose epirubicin plus cisplatin in small cell lung cancer with granulocyte-macrophage colony-stimulating factor use when appropriate Seminars in Oncology 21(1 Suppl 1: 48-53Fennelly, D.W.; Aghajanian, C.; Shapiro, F.; O'Flaherty, C.; O'Connor, K.; Curtin, J.P.; Crown, J.P.; Hoskins, W.J.; Spriggs, D.R. 1997: Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer Seminars in Oncology 24(1 Suppl 2: S2
Rosenblatt, K.A.; Thomas, D.B.; Noonan, E.A. 1992: High-dose and low-dose combined oral contraceptives: protection against epithelial ovarian cancer and the length of the protective effect. the WHO Collaborative Study of Neoplasia and Steroid Contraceptives European Journal of Cancer 28a (11): 1872-1876
Rosenblatt, K.A.; Thomas, D.B.; Noonan, E.A. 1992: High-dose and low-dose combined oral contraceptives: protection against epithelial ovarian cancer and the length of the protective effect. the WHO Collaborative Study of Neoplasia and Steroid Contraceptives European Journal of Cancer 28a (11): 1872-1876
Hua, X.-m.; Ren, X.-w.; Liu, F.-l.; Liu, Y.; Zhang, C.-j.; Li, Z.-j.; Xu, L.; Liu, J.-y.; Liu, Y.-g. 2004: Comparision of high dose impulsion and low dose density chemotherapeutic regimens with paclitaxel plus cisplatin in advanced NSCLC Zhonghua Zhong Liu Za Zhi 26(10): 621-625
Torelli, F.; Catanzaro, F.; Conti, G.; Comeri, C.G.; Risi, O.; Pino, R.; Lissoni, G.; Borin, R.; Minocci, D.; Monesi, G.; Baresi, A.; Perego, S.; Caruso, G.M.; Scardino, G. 2001: High-dose epirubicin in the prophylactic treatment of T1G2 superficial bladder tumors European Urology 39(Suppl): 11-14
Nicolaides, C.; Giannakakis, T.; Skarlos, D.; Athanassiadis, A.; Fountzilas, G.; Damigos, D.; Pavlidis, N. 1998: Tropisetron in the prevention of acute nausea and vomiting in patients treated with high dose epirubicin Journal of Experimental and Clinical Cancer Research: Cr 17(1): 71-75
Wilailak, S.; Tresukosol, D.; Linasmita, V.; Termrungruanglert, W. 2000: Phase Ii study of high-dose paclitaxel in platinum-refractory epithelial ovarian cancer European Journal of Gynaecological Oncology 21(6): 610-612
Deng, C.; Huang, R.; Lian, L. 1996: Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer Zhonghua Fu Chan Ke Za Zhi 31(3): 159-162
Fukuyama, A.; Yokoyama, Y.; Wada, J.; Hashimoto, T.; Oda, T.; Sato, S.; Mizunuma, H. 2009: Two cases of ovarian cancer at an early stage incidentally detected using transvaginal ultrasonography in screening: importance of interval for ovarian cancer screening and selection of population with a high risk of ovarian cancer European Journal of Gynaecological Oncology 30(2): 208-210
Kotz, K.W.; Schilder, R.J. 1995: High-dose chemotherapy and hematopoietic progenitor cell support for patients with epithelial ovarian cancer Seminars in Oncology 22(3): 250-262
Panici, P.B.; Scambia, G.; Baiocchi, G.; Laurelli, G.; Greggi, S.; Battaglia, F.; Ragusa, G.; Salerno, G.; Gallo, A.; Cento, R. 1990: Rationale for very high-dose chemotherapy with peripheral blood stem cell support in advanced ovarian cancer Haematologica 75(Suppl 1): 87-89
Scarfone, G.; Villa, A.; Parazzini, F.; Sciatta, C.; Polverino, G.; Bolis, G. 1999: A phase I-II trial of high-dose ifosfamide in patients with ovarian cancer refractory or resistant to platinum and/or paclitaxel-containing chemotherapy Tumori 85(4): 217-219
Mukaiyama, T.; Ogawa, M.; Horikoshi, N.; Inoue, K.; Aiba, K.; Matsuoka, A.; Matsumura, T.; Ogihara, A.; Sumida, T. 1992: High-dose thio-TEPA with escalating doses of epirubicin and autologous hematopoietic stem cell transplant for refractory cancers Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(2): 189-194
Murray, N. 1987: The importance of dose and dose intensity in lung cancer chemotherapy Seminars in Oncology 14(4 Suppl 4: 20-28
Yen, M.L.; Chen, Y.C.; Lin, M.T.; Liu, M.C.; Tang, J.L.; Wang, C.H.; Hsieh, C.Y. 1992: High-dose chemotherapy with support by autologous bone marrow and GM-CSF in the treatment of advanced ovarian cancer: preliminary report of a new strategy Transplantation Proceedings 24(4): 1533-1535
Kusumoto, S.; Naito, H.; Imazu, K.; Kai, I.; Hamasaki, A.; Kazusa, Y.; Nakashima, Y.; Kodama, M.; Kumagai, M.; Ueda, K. 2017: Clinical Study to Determine the Dose Intensity of BEP Chemotherapy for Ovarian Malignant Germ Cell Tumors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 44(3): 255-259
Sevelda, P.; Dittrich, C.; Salzer, H.; Pateisky, N.; Spona, J. 1986: Monitoring the cytotoxic potential of a sequential polychemotherapy (adriamycin/cisplatin-vincristine/cyclophosphamide-high dose methotrexate) in patients with advanced ovarian cancer with the tumor marker CA-125 Cancer Detection and Prevention 9(5-6): 521-528
Kootte, A.M.; Lensen, L.M.; van Bockel, J.H.; Paul, L.C. 1988: A randomized study comparing high- and low-dose regimens of cyclosporine in renal transplantation Transplantation Proceedings 20(3 Suppl 3: 136-139
van Heusden, A.M.; Coelingh Bennink, H.J.T.; Fauser, B.C.J.M. 2002: FSH and ovarian response: spontaneous recovery of pituitary-ovarian activity during the pill-free period vs. exogenous recombinant FSH during high-dose combined oral contraceptives Clinical Endocrinology 56(4): 509-517